58.99
1.17 (2.02%)
| Penutupan Terdahulu | 57.82 |
| Buka | 58.52 |
| Jumlah Dagangan | 1,419,342 |
| Purata Dagangan (3B) | 2,054,359 |
| Modal Pasaran | 11,401,848,832 |
| Harga / Pendapatan (P/E TTM) | 42.44 |
| Harga / Pendapatan (P/E Ke hadapan) | 11.57 |
| Harga / Jualan (P/S) | 3.52 |
| Harga / Buku (P/B) | 1.79 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 3 Aug 2026 |
| Margin Keuntungan | 17.76% |
| Margin Operasi (TTM) | 30.05% |
| EPS Cair (TTM) | 2.70 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 14.80% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 109.40% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 10.39% |
| Nisbah Semasa (MRQ) | 5.52 |
| Aliran Tunai Operasi (OCF TTM) | 700.26 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 411.56 M |
| Pulangan Atas Aset (ROA TTM) | 6.38% |
| Pulangan Atas Ekuiti (ROE TTM) | 9.64% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | BioMarin Pharmaceutical Inc. | Bercampur | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | 2.0 |
| Purata | -0.33 |
|
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Growth |
| % Dimiliki oleh Orang Dalam | 0.77% |
| % Dimiliki oleh Institusi | 98.91% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |